Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰ • واحد: scale
حداقل ۰ — حداکثر ۱۰ • واحد: scale
حداقل ۰ — حداکثر ۱۰ • واحد: scale
حداقل ۰ — حداکثر ۱۰ • واحد: scale
حداقل ۰ — حداکثر ۳۰۰ • واحد: mg/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Inactive Disease0–1.3
- Moderate Disease Activity1.3–2.1
- High Disease Activity2.1–3.5
- Very High Disease Activity3.5–10
The Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP) calculates classifying inflammatory arthritides and monitoring longitudinal autoimmune disease activity. Key inputs include back pain. Scores guide initiating or optimizing disease-modifying antirheumatic drugs (DMARDs) or targeted biologic therapies. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stratifies severity of ankylosing spondylitis (AS) using clinical and laboratory data, specifically CRP. ASAS-endorsed disease activity score for monitoring AS treatment response.
Clinical Indication
The Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP) is indicated for bedside clinical practice to support Stratifies severity of ankylosing spondylitis (AS) using clinical and laboratory data, specifically CRP. ASAS-endorsed disease activity score for monitoring AS treatment response.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with inflammatory arthritis, systemic lupus erythematosus, systemic vasculitis, or autoimmune connective tissue disorders. Clinical application is indicated across Rheumatology clinics, connective tissue disease units, and academic medical centers.
Limitations & Contraindications
Elevated erythrocyte sedimentation rate (ESR) and CRP are non-specific acute phase reactants that can reflect occult systemic infection.
Clinical Pearls & Action Plan
Serological autoantibody testing must strictly correlate with inflammatory joint patterns and objective synovial pathology. Guideline pearl: The score is endorsed by the Assessment of SpondyloArthritis international Society (ASAS) and is the recommended outcome measure for clinical trials..
ASDAS-CRP = 0.12 × Back Pain + 0.06 × Duration of Morning Stiffness + 0.11 × Patient Global + 0.07 × Peripheral Pain/Swelling + 0.58 × Ln(CRP+1). Cut-offs: <1.3 (inactive), 1.3-2.1 (moderate), 2.1-3.5 (high), >3.5 (very high).
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| back_pain | float | Yes | Overall level of AS neck, back, or hip pain (0-10 scale)(scale) |
| morning_stiffness | float | Yes | Overall level of morning stiffness from the time you wake up (0-10 scale)(scale) |
| patient_global | float | Yes | Patient global assessment: How active was your spondylitis on average during the last week (0-10 scale)(scale) |
| peripheral_pain | float | Yes | Overall level of pain/swelling in joints other than neck, back, or hips (0-10 scale)(scale) |
| crp | float | Yes | C-reactive protein (CRP) level(mg/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1.3 | Inactive Disease | Inactive ankylosing spondylitis |
| 1.3–2.1 | Moderate Disease Activity | Moderate ankylosing spondylitis activity |
| 2.1–3.5 | High Disease Activity | High ankylosing spondylitis activity |
| 3.5–10 | Very High Disease Activity | Very high ankylosing spondylitis activity |
Evidence-Based References (EBM)
- Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870.DOI: 10.1136/ard.2008.094870
- van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, Braun J, Landewé R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Dec;68(12):1811-8. doi: 10.1136/ard.2008.100826.DOI: 10.1136/ard.2008.100826
- Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011 Jan;70(1):47-53. doi: 10.1136/ard.2010.138594.DOI: 10.1136/ard.2010.138594